Human Lactoferrin/Human Serum Albumin Fusion Protein Strongly Inhibits Cancer Cell Migration Related to Cancer Metastasis by Disrupting Golgi pH Homeostasis in Cancer Cells
NQ Score
87/100
N1 Content Completeness
90
AI Summary (NQ-processed)
A research group at Tokyo University of Technology discovered that a fusion protein of human lactoferrin and human serum albumin (hLF-HSA) strongly inhibits cancer cell migration by disrupting Golgi pH homeostasis. This finding is expected to lead to the development of new drug discovery strategies and was published in the international scientific journal "FEBS Open Bio" on March 24, 2026.
AI Analysis
Frequently Asked Questions
- Q: What is hLF-HSA?
- A: It is a fusion protein combining lactoferrin and human serum albumin, expected to inhibit cancer cell metastasis.
- Q: What are the main findings of this research?
- A: Two mechanisms were elucidated: hLF-HSA disrupts the pH homeostasis of the Golgi apparatus in cancer cells and strongly inhibits cell migration.
- Q: How does this research contribute to cancer treatment?
- A: It opens up new drug development strategies for inhibiting cancer metastasis and the potential for selective treatments with fewer side effects.